A Minimalist Design Looks Great for Clearing Tau
Interception of Extracellular Tau by Antibodies May Be Sufficient to Stop the Spread of Tau in AD
Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
For full access to this article login to GEN Select now.
Biopharma R&D Spending for 2012 Under Seige
Restructuring and Budgetary Cuts Threaten to Lower Industry Expenditures
- On March 16, Novartis said that it will decrease R&D in the U.K. with reports putting the number of jobs to be cut between 400 and 550. This places the pharma giant in the company of GlaxoSmithKline, Merck & Co., Pfizer, and Roche. Over the past two years all ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.